Press "Enter" to skip to content

What to look out for in Biotech Stocks in 2021

Biotechnology touches a wide area of companies, food production, and spanning genomics to biofuels and other niche industries. However, most of the time, the word biotech summons up images of pharmaceuticals and medicine only. So the Biotech Stocks in the sector center only on these two areas.

Here are a number of Biotech Stocks to keep an eye on in 2021:

  • Johnson & Johnson (NYSE:JNJ) 
  • Exelixis (NASDAQ:EXEL)
  • Agios Pharmaceuticals (NASDAQ:AGIO)
  • Novavax (NASDAQ:NVAX)
  • Moderna (NASDAQ:MRNA)
  • Sage Therapeutics (NASDAQ:SAGE)
  • Vertex (NASDAQ:VRTX)

Johnson & Johnson

Janssen, JNJ’s pharmaceutical arm, is one of the most discussed biotech in the market these days. The company is recorded massive growth since the pandemic started. And with the Delta variant cases on the rise, the company is anticipating bolstering investments in coming times.

Exelixis (EXEL) 

The stocks for Exelixis are relatively cheap. The stocks are being traded around USD20 and are expected to reach USD31.69. If the stocks manage to reach the price-target range, the shares have the strength to get tripled in price in the near future.

Agios Pharmaceuticals (AGIO) 

Lately, Agios Pharmaceuticals recorded a loss of USD86.2 million for the second quarter of 2021. However, the company’s announcement on August 17, 2021, regarding FDA’s approval on Mitapivat, a treatment for adults with pyruvate kinase (PK) deficiency, has brought new investments to the firm.

Novavax (NVAX)

The firm is in talks mainly because of its vaccine approval. The firm is waiting for good news from FDA. It even has received an order of 100 million doses and got USD1.6 billion from the US government. According to analysts, with the growth in demand, Novavax is likely to experience a spike in growth in the near future.

Moderna (MRNA) 

Moderna has already witnessed a huge gain in recent times. However, the analysts believe that the company is way too far from done. The projections state that Moderna will record revenues of around USD20 billion in 2021.

Be First to Comment


メールアドレスが公開されることはありません。 が付いている欄は必須項目です